Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
31 March 2020 | Story Leonie Bolleurs | Photo Supplied
UFS Covid-19 vaccine research team
Prof Robert Bragg and members of the Veterinary Biotechnology research group believe that finding a vaccine for COVID-19 will not be a ‘quick fix’. From the left are: Prof Bragg, Samantha McCarlie, Liese Kilian, and Dr Charlotte Boucher-van Jaarsveld. The photo was taken during the World Veterinary Poultry Association congress in Thailand in 2019.

On 31 March 2020, there were 804 061 coronavirus cases and 39 064 deaths globally due to the outbreak. According to media reports, there is still no licensed vaccine for COVID-2019 – the cause of our current global health emergency.  

Prof Robert Bragg, researcher at the University of the Free State (UFS), says this is without a doubt the most pressing research need in the world today. 

The Veterinary Biotechnology research group in the Department of Microbial, Biochemical, and Food Biotechnology at the UFS recently submitted an article for publication on the design of a possible COVID-19 vaccine, based on work they have done on infectious bronchitis virus (also a coronavirus). The article, authored by the group of which Prof Bragg is a member, is titled: A sub-unit vaccine produced in 'Yarrowia lipolytica' against COVID-19: Lessons learnt from infectious bronchitis virus. 

The research group, consisting of researchers and postgraduate students, is mostly looking at strategies for improved disease control, mainly in avian species, through vaccine development, treatment, and biosecurity.

Prof Bragg says their main aim with this study was to get the research out there so that the bigger pharmaceutical companies could take up the design of a possible COVID-19 vaccine and assist with the development of a vaccine. 

He says the research group’s role in this lengthy process would be to express the protein, which could be used in the development of a possible vaccine. “Thereafter, it will have to be taken up by a vaccine manufacturer to get the vaccine made and to the market.”

Developing a vaccine
Liese Kilian, a member of the research group, finished writing up her MSc thesis in Microbiology in the UFS Department of Microbial, Biochemical, and Food Biotechnology in December 2019 – the same time that COVID-19 originated in China. She has been working on the development of an edible sub-unit vaccine against the infectious bronchitis virus (IBV), which is a widespread avian coronavirus. This virus is specific to poultry and is different from COVID-19. 

Kilian’s project was conducted under the supervision of Prof Bragg and Dr Charlotte Boucher-van Jaarsveld. Dr Boucher-van Jaarsveld is a research fellow in the university’s Department of Microbial, Biochemical and Food Biotechnology.

Kilian, with the assistance of Samantha Mc Carlie, currently a master’s student in the research group, substituted the genetic code of the IBV with the genetic code of the COVID-19 virus, which were already published at that stage. Thus, a gene for the development of a possible sub-unit vaccine against the S1 spike protein of COVID-19 was developed for expression in the same yeast strain used to express the spike protein of IBV. A sub-unit vaccine can be described as part of a pathogen, triggering an immune response against the pathogen from which it is derived.

After Killian successfully developed the gene for this study, she expressed the S1 spike protein of the IBV in a yeast-based expression system developed by the research group. Dr Boucher-van Jaarsveld says this simply means that the yeast takes up the foreign genetic material (viral gene) into its own genetic make-up and makes more of this protein as if it is part of the yeast’s normal material. 

“The images of COVID-19 are being shown constantly in the media and the ‘spikes’ can be seen on all of these images. These spikes are very typical for all coronaviruses and there is some level of similarity between the structure of these spikes in many of the coronaviruses,” Prof Bragg adds.

According to the World Health Organisation, the spike protein is a promising candidate for a sub-unit vaccine due to its immunogenicity and safety, as well as manufacturing and stability considerations during large-scale development.

Prof Bragg says there are many different expression systems that are widely used. Producing the sub-unit vaccine in a yeast species is beneficial for the work they are doing. A yeast expression system is favourable as large-scale production, is less expensive compared to mammalian cell lines, and can be applied as an edible vaccine.

“The technology to grow massive volumes of yeast are also very well established. This, after all, is how beer is made!” Prof Bragg says. Dr Boucher-van Jaarsveld adds: “The expression of an antigen is not necessarily just geared towards vaccines but can also be used in the development of diagnostic tests to screen populations for infections.”

Working with other researchers
“Now that the situation is all but out of control, we maybe need to investigate the possibilities of working with other key researchers at the UFS as well as other universities in South Africa to develop the vaccine or diagnostic reagents locally. Discussions on this aspect are already underway.”

Several other universities in South Africa are also working to find a cure for the virus. Government availed funding for more research on the matter. According to Higher Education, Science and Technology Minister, Blade Nzimande, the University of Cape Town, the Council for Scientific and Industrial Research, as well as the Vaccines Institute of Southern Africa are working on the development of a vaccine.

Prof Bragg expressed the hope of obtaining funding for this work. “Because without funding, we will not be able to do anything with this data,” he says. They are currently investigating different funding options. 

“The sooner we start on the development of a vaccine, the sooner there will be one, but it will not be a ‘quick fix’. It must be stressed that, even if vaccine development is fast-tracked through the regulatory bodies, it will take many months (if not years) to move from the laboratory to the first human experimentation. It will take even longer before any human vaccine can be rolled out,” says Prof Bragg.



News Archive

Chemistry research group receives international recognition
2016-10-28

Description: Chemistry research group  Tags: Chemistry research group

Dr Carla Pretorius mounts microcrystals with
Dumisani Kama while Pennie Mokolokolo
observe the technique.
Photo: Supplied


Crystals and crystallography form an integrated part of our daily lives, from bones and teeth, to medicines and viruses, new catalysts, jewellery, colour pigments, chocolates, analysing rocks on the moon and Mars, electronics, batteries, metal blades in airplane turbines, panels for solar energy and many more.

In spite of this, not many people know much about X-ray crystallography, although it is probably one of the greatest innovations of the 20th century, spanning the sciences. That is why this discipline is actively researched by a number of tertiary institutions around the globe as well as the Inorganic Chemistry Group of the Department of Chemistry at the University of the Free State (UFS).

Research by the Inorganic Chemistry Group includes:
•    clever design of model medicines to better detect cancer and study heart, bone and brain defects;
•    production of new compounds for making new and better automobile fuels and decrease carbon dioxide in the atmosphere;
•    generation and purification of new South African mineral resources for metals widely used in turbines which use wind energy.

A group of UFS students have received acknowledgement for their research at six international venues in the past few months.

Posters in Cameroon
Twelve postgraduate students, together with Prof André Roodt, Head of the Inorganic Chemistry division at the UFS, delivered three oral presentations, nine posters, one plenary and one keynote lecture abroad.

Four UFS students - Nina Morogoa, Pheello Nkoe, Alebel Bilay, and Mohammed Elmakki - who delivered posters at the First Pan African Conference on Crystallography in Dschang, Cameroon, received prizes for their presentations.

School and conference in Croatia

Students Orbett Alexander and Dumisani Kama were selected to attend the intense and demanding Third European Crystallographic School in Bôl, Croatia. Both Kama, Alexander and Prof Roodt gave oral presentations at the 24th Croatian-Slovenian Crystallographic Meeting at Brac Island, Croatia.

Kama, together with Dr Ferdi Groenewald, Dr Carla Pretorius and Pennie Mokolokolo, also attended the European Synchrotron Radiation Facility (ESRF) in Grenoble, France. The ESRF is a centre of excellence for fundamental and innovation-driven research. The storage ring at this laser facility can generate X-rays 100 billion times brighter than typical medical and laboratory X-ray sources.

Research in Switzerland

Kama and Mokolokolo also spent one month on research visits at the University of Zurich in Switzerland. Both Kama and Alexander were invited to present their research orally to the Institute of Inorganic Chemistry in Zurich, headed by Prof Roger Alberto.

In Basel, Switzerland, Dr Ferdi Groenewald, Dr Renier Koen, and Dr Truidie Venter all presented their research at the 30th European Crystallographic Meeting.

Prof Roodt said: “It is incredibly important that our postgraduate students get the chance to interact, discuss, and be taught by the best in the world and realise that hard work on basic and applied chemistry processes leads to broader recognition. The delegates to these international venues came from more than 60 countries and took note of our students work. With these young researchers, our future at the UFS and at Inorganic Chemistry is in good hands”.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept